Targeting endothelial cell dysfunction and vascular remodelling to stop progression of advanced pulmonary fibrosis

针对内皮细胞功能障碍和血管重塑以阻止晚期肺纤维化的进展

• 批准号: 388857
• 负责人: Kolb Martin R
• 金额: $ 54.62万
• 依托单位: McMaster University
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-09-01 至 2023-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=388857&lang=en
• 关键词: Biomarker Studies In Humans; Experimental Model Of Lung Fibrosis; Experimental Model Of Pulmonary Hypertension

Lung fibrosis affects approximately 14,000 Canadians, about half of them dying within 3-4 years. The disease origin is often unknown. It is characterized by relentless scarring, causing stiffening of the lungs and progressive shortness of breath until dea

肺纤维化影响了大约14,000名加拿大人，其中约一半人在3-4年内死亡。这种疾病的来源通常是未知的。它的特征是无休止的疤痕，导致肺部僵硬和进行性呼吸急促，直到DEA